MOLECULAR PARTNERS ADS/1 (6ML0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MOLECULAR PARTNERS ADS/1 (6ML0) has a cash flow conversion efficiency ratio of -0.139x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.15 Million ≈ $-13.04 Million USD) by net assets (€80.33 Million ≈ $93.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MOLECULAR PARTNERS ADS/1 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how MOLECULAR PARTNERS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 6ML0 total liabilities for a breakdown of total debt and financial obligations.
MOLECULAR PARTNERS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MOLECULAR PARTNERS ADS/1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hitejinro Holdings
KO:000140
|
0.088x |
|
Midas Minerals Ltd
AU:MM1
|
-0.189x |
|
Unicycive Therapeutics Inc
NASDAQ:UNCY
|
-0.159x |
|
MKH Bhd
KLSE:6114
|
0.032x |
|
B’IN Live Co Ltd
TW:6625
|
0.138x |
|
Blaize Holdings, Inc.
NASDAQ:BZAI
|
-19.079x |
|
UBM Development AG
VI:UBS
|
-0.015x |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
0.004x |
Annual Cash Flow Conversion Efficiency for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual cash flow conversion efficiency of MOLECULAR PARTNERS ADS/1 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of MOLECULAR PARTNERS ADS/1.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €80.33 Million ≈ $93.92 Million |
€-51.26 Million ≈ $-59.92 Million |
-0.638x | -52.53% |
| 2024-12-31 | €141.64 Million ≈ $165.59 Million |
€-59.25 Million ≈ $-69.27 Million |
-0.418x | -25.08% |
| 2023-12-31 | €176.43 Million ≈ $206.26 Million |
€-59.01 Million ≈ $-68.98 Million |
-0.334x | -166.33% |
| 2022-12-31 | €235.17 Million ≈ $274.93 Million |
€118.57 Million ≈ $138.62 Million |
0.504x | +159.47% |
| 2021-12-31 | €107.29 Million ≈ $125.43 Million |
€-90.95 Million ≈ $-106.33 Million |
-0.848x | -- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more